Monday, November 9, 2015
EMD Millipore, the life science business of Darmstadt, Germany-based Merck, has entered into a strategic alliance with Turgut Ilac, a biosimilars company based in Turkey, to provide its Provantage End-to-End services for development and manufacturing of biologics.
Darmstadt, Germany-based Merck has re-launched its visual identity. The fundamental revision of the visual appearance—as well as the introduction of new logos for its U.S. businesses EMD Serono, EMD Millipore and EMD Performance Materials—reflects a transformation into a global science and technology company.
Merck Millipore, the life science business of German-based Merck, is collaborating with celares, a privately owned biopharmaceuticals company, to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The new service offering enabled by the collaboration includes feasibility studies, process and analytical development and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.
EMD Millipore, the life science business of Merck of Darmstadt, Germany, has announced an agreement for providing upstream process development services for Precision Biologics, a Texas-based clinical-stage biotechnology company, to advance a preclinical monoclonal antibody. The antibody, NEO-201, binds to a tumor-specific antigen found in several forms of cancer, offering therapeutic potential across multiple cancer types, including colorectal, lung, ovarian and pancreatic, an especially deadly cancer with limited treatment options.
North Shore InnoVentures (NSIV), a New England technology incubator and business accelerator, has received a capital grant of $1.65 million from the Massachusetts Life Sciences Center (MLSC). The grant will allow NSIV to expand its current laboratory facilities over the next three years and purchase advanced analytical instrumentation. This grant is part of a larger $5 million award to the Life Sciences Consortium of the North Shore (LSCNS), consisting of Endicott College, Gordon College, North Shore InnoVentures, North Shore Community College and Salem State University, that will fund major lab/facility and equipment upgrade projects at the member institutions and organizations.
Luminex has extended their global supply and distribution agreement with EMD Millipore—the life science division of Merck, of Darmstadt, Germany. Luminex develops, manufactures and markets innovative biological testing technologies with applications throughout the clinical diagnostic and life science industries.
Ark Therapeutics, a London-based contract development and manufacturing company focused on viral product, has signed a non-binding letter of intent with EMD Millipore, a division of Merck, to enter into a collaborative agreement in the field of viral based bioengineered vaccines and other live viral products manufacturing.